Shane Hegarty

Shane Hegarty

Company: AXONIS Therapeutics

Job title: Chief Scientific Officer & Co-Founder


In-Vivo Phenotypic Screens Identify Therapeutic Targets for Common Pathological Problems in Neurological Disorders 9:30 am

In vivo phenotypic screens identify therapeutic targets underlying common pathological problems in neurodegenerative and neurological disorders Neurotrauma-related degeneration causes excitation/inhibition imbalance in spared nervous system tissue, but KCC2-enhancing therapies can restore lost functions KCC2-enhancing treatments are promising therapies for rare and genetic disorders involving excitation/inhibition imbalance and neuronal circuit disinhibition in the CNSRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.